Join
Live feed
·
PRReleasevia Quantisnow
Avalo Therapeutics Inc. logo

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

ByQuantisnow·Wall Street's wire, on your screen.
AVTX· Avalo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVTX (Avalo Therapeutics Inc.) and more on Quantisnow.

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event | Quantisnow